Abstract
The increasing use of more complex multiagent treatments and multimodal delivery of antineoplastic therapies has resulted in a growing number of cardiovascular complications resulting in cardiotoxicity. These complications may manifest as a relatively benign cardiac dysrhythmia to potentially life-threatening conditions such as hypertensive crisis, myocardial infarction, and heart failure. Prevention, early detection, and continuous monitoring should be the guiding principles in the management of cancer patients receiving these therapies.
